与肺动脉高压诊断和精准治疗相关的新型生物标志物

Novel biomarkers for diagnosis and precision treatment of pulmonary arterial hypertension

肺动脉高压是一类以肺血管阻力进行性升高为主要特征的疾病,致残率和病死率都很高。由于多种疾病均可导致肺动脉高压的发生,因此其机制研究发展迅速,也出现了针对肺高压多种发病机制及其不同环节而研发的新型靶向药。综述目前与肺动脉高压发病机制相关的新型生物标志物,并将其按照功能进行分类,包括内皮细胞功能失调、炎症、表观遗传学、心脏功能、氧化应激、细胞外基质等内容,为该病的临床早期诊断、疾病分型、严重程度判断等提供有效依据,进而为精准治疗以及新药研发提供依据。

Pulmonary arterial hypertension is characterized by elevated pulmonary arterial pressure with high disabled rate and lethality. Since many causes could lead to pulmonary arterial hypertension, the mechanism studies were developed rapidly, and some new therapeutic targets have been explored according to the multiple pathogenic mechanisms and pathways. We summarized the potential and novel biomarkers of the mechanisms associated with pulmonary arterial hypertension, and categorized based on their relationship to endothelial cell dysfunction, inflammation, epigenetics, cardiac function, oxidative stress, extracellular matrix, etc. The biomarkers can help for diagnosis, sorting, disease severity assessment of PAH, in order to provide the basis for precision treatment and new therapeutic target development.